Phase I trial of proteasome inhibition with bortezomib (BOR) with concurrent chemoradiation (chemoXRT) for stage III non-small cell lung cancer (NSCLC)
2005 ◽
Vol 23
(16_suppl)
◽
pp. 7300-7300
Keyword(s):
Phase I
◽